Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 314 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy
Interventions
TRV130, Moxifloxacin, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

NCT02785770
Conditions
Healthy
Interventions
PF-04447943, Placebo, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Healthy
Interventions
Ponesimod Placebo, Moxifloxacin Placebo, Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg, Ponesimod 60 mg, Ponesimod 80 mg, Ponesimod 100 mg, Moxifloxacin 400 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 45 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evansville, Indiana
Completed Phase 4 Interventional Results available

Moxifloxacin vs. Polytrim for Conjunctivitis

NCT00581542
Conditions
Conjunctivitis
Interventions
moxifloxacin, polytrim
Drug
Lead sponsor
University of Rochester
Other
Eligibility
1 Year to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Rochester, New York
Conditions
Healthy
Interventions
mipomersen sodium, moxifloxacin hydrochloride (Avelox®), placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Conditions
Healthy Participants
Interventions
EPX-100, EPX-100-Matching Placebo, Moxifloxacin, Moxifloxacin-Matching Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Corneal Transplantation
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Boynton Beach, Florida • Indianapolis, Indiana • Great Rapids, Michigan + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

NCT01460368
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2409021, Placebo, Moxifloxacin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Females

NCT01373931
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Ortho Cyclen, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Healthy Male Volunteers
Interventions
NXL104, Ceftaroline, Placebo Infusion, Ceftazidime, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Healthy Volunteers
Interventions
BMS-986419, BMS-986419 Matching Placebo, Moxifloxacin, Moxifloxacin Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

NCT01860703
Conditions
Prolonged QTc Interval
Interventions
Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Healthy Subjects
Interventions
A: pacritinib, B: Placebo, C: moxifloxacin
Drug · Other
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Completed Phase 1 Interventional Accepts healthy volunteers

CAEB071 Thorough QTc Study in Healthy Volunteers

NCT01594255
Conditions
Healthy
Interventions
sotrastaurin, placebo to sotrastaurin, Avelox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Fort Lauderdale, Florida + 5 more
Conditions
Alzheimer Disease
Interventions
BMS-708163, Placebo, Moxifloxacin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Healthy
Interventions
Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers

AZD3293 Thorough QT Study in Healthy Male Volunteers

NCT02040987
Conditions
Alzheimer's Disease
Interventions
AZD3293, Placebo, Moxifloxacin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Postpartum Hemorrhage
Interventions
Carbetocin, Placebo, Placebo and Moxifloxacin
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Pediatric ALL
Interventions
Standard of care drug
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Parkinson's Disease, Off Episodes of Parkinson Disease
Interventions
APL-130277, Placebo, Moxifloxacin
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more
Conditions
Healthy
Interventions
MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI

NCT05493280
Conditions
Hyperpigmentation
Interventions
MOXI
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dallas, Texas